Massachusetts firms Cubist Pharmaceuticals Inc. and Alnylam Pharmaceuticals Inc. have formed a 50-50 North American partnership to develop and commercialize Alnylam's respiratory syncytial virus (RSV)-specific RNAi therapeutics. (BioWorld Today) Read More
No AbstractMechelen, Belgium-based Galapagos NV signed its fifth major pharmaceutical alliance, inking a potential €171.5 million (US$230.4 million)-plus deal with Merck & Co. Inc. to develop drugs aimed at the obesity and diabetes markets. Read More
